Update on Current Care Guideline : Multiple sclerosis
Treatment for relapsing-remitting multiple sclerosis (RRMS) is initiated upon fulfillment of new McDonald 2010 criteria for RRMS. In addition, lumbar puncture is an essential diagnostic method. Interferon-β, dimethyl fumarate, glatiramer acetate and teriflunomide are the first-line immunomodulating drugs (IMD) for RRMS. If the disease is active according to clinical or MRI evaluation during the first-line IMD treatment, alemtuzumab, fingolimod or natalizumab may be considered as second-line therapies. IMD treatment is discontinued upon the transition of RRMS to secondary progressive phase. Rehabilitation should be considered at every phase of the disease.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:131 |
|---|---|
| Enthalten in: |
Duodecim; laaketieteellinen aikakauskirja - 131(2015), 5 vom: 01., Seite 500-1 |
| Sprache: |
Finnisch |
|---|
| Weiterer Titel: |
Kaypa hoite-suosituksen paivitystiivistelma. MS-tauti |
|---|
| Beteiligte Personen: |
Remes, Anne [VerfasserIn] |
|---|
| Themen: |
Antibodies, Monoclonal, Humanized |
|---|
| Anmerkungen: |
Date Completed 21.08.2015 Date Revised 04.08.2015 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM251490211 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM251490211 | ||
| 003 | DE-627 | ||
| 005 | 20231224162127.0 | ||
| 007 | tu | ||
| 008 | 231224s2015 xx ||||| 00| ||fin c | ||
| 028 | 5 | 2 | |a pubmed24n0838.xml |
| 035 | |a (DE-627)NLM251490211 | ||
| 035 | |a (NLM)26237913 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fin | ||
| 100 | 1 | |a Remes, Anne |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Update on Current Care Guideline |b Multiple sclerosis |
| 246 | 3 | 3 | |a Kaypa hoite-suosituksen paivitystiivistelma. MS-tauti |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 21.08.2015 | ||
| 500 | |a Date Revised 04.08.2015 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Treatment for relapsing-remitting multiple sclerosis (RRMS) is initiated upon fulfillment of new McDonald 2010 criteria for RRMS. In addition, lumbar puncture is an essential diagnostic method. Interferon-β, dimethyl fumarate, glatiramer acetate and teriflunomide are the first-line immunomodulating drugs (IMD) for RRMS. If the disease is active according to clinical or MRI evaluation during the first-line IMD treatment, alemtuzumab, fingolimod or natalizumab may be considered as second-line therapies. IMD treatment is discontinued upon the transition of RRMS to secondary progressive phase. Rehabilitation should be considered at every phase of the disease | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Practice Guideline | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Immunologic Factors |2 NLM | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 700 | 1 | |a Airas, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Atula, Sari |e verfasserin |4 aut | |
| 700 | 1 | |a Färkkilä, Markus |e verfasserin |4 aut | |
| 700 | 1 | |a Hartikainen, Päivi |e verfasserin |4 aut | |
| 700 | 1 | |a Koivisto, Keijo |e verfasserin |4 aut | |
| 700 | 1 | |a Mäenpää, Eliisa |e verfasserin |4 aut | |
| 700 | 1 | |a Ruutiainen, Juhani |e verfasserin |4 aut | |
| 700 | 1 | |a Sumelahti, Marja-Liisa |e verfasserin |4 aut | |
| 700 | 0 | |a Päivitystiivistelmä |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Duodecim; laaketieteellinen aikakauskirja |d 1945 |g 131(2015), 5 vom: 01., Seite 500-1 |w (DE-627)NLM000016136 |x 0012-7183 |7 nnns |
| 773 | 1 | 8 | |g volume:131 |g year:2015 |g number:5 |g day:01 |g pages:500-1 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 131 |j 2015 |e 5 |b 01 |h 500-1 | ||